Melanotan II

Melanotan II is a synthetic analog of alpha-melanocyte-stimulating hormone (alpha-MSH) originally investigated as a sunless tanning agent. It has drawn broader research and off-label interest because melanocortin receptor activation also appears to influence appetite and sexual arousal in some studies. Melanotan II is not approved by the FDA or comparable regulatory bodies for any indication, and formulations sold outside clinical channels vary in purity and concentration. Reported effects and risks are drawn largely from small studies, case reports, and anecdotal use rather than large-scale controlled trials. Because of its broad receptor activity, it is generally regarded as having a less selective profile than newer melanocortin agonists such as bremelanotide. Reported benefits include studied for stimulating melanogenesis, producing a tanning effect without prolonged uv exposure, reported secondary effects on libido in some users and small studies, may be associated with appetite suppression in early research.

Reported ranges run 250-1,000 mcg. A low protocol is 250 mcg once daily during initial loading phase, and a high protocol is 1,000 mcg once daily, used by some during aggressive loading protocols. This is reference information, not a dosing recommendation.

Reported as roughly 2 to 4 hours in available pharmacokinetic literature, though pigmentation effects persist well beyond plasma clearance due to sustained melanocyte activation.. That is what sets the dosing frequency, and it is why the timing guidance is evening.

Subcutaneous: into fat, under the skin.

Commonly described loading phase of daily dosing for 1 to 3 weeks to establish pigmentation on, followed by Maintenance dosing reduced to 1-2 times weekly, or discontinued once desired pigmentation is reached off. Because Melanotan II is not a regulated pharmaceutical product, dosing patterns reported in user communities are not standardized or clinically validated.

Reported side effects include nausea, particularly with early or higher doses, flushing and facial reddening, spontaneous or exaggerated skin darkening, including of moles, reports of new mole formation or changes in existing moles, which may warrant dermatological evaluation, darkening of freckles and increased skin pigmentation unevenness. Evidence level for this compound is moderate evidence.